Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
LPTX

LPTX - Leap Therapeutics Inc Stock Price, Fair Value and News

$0.87+0.05 (+6.10%)
Market Closed

4/100

LPTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

4/100

LPTX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.85

Target 3M

$0.95

Target 6M

$0.9

LPTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LPTX Price Action

Last 7 days

-21.7%

Last 30 days

-29.1%

Last 90 days

72.9%

Trailing 12 Months

-62.3%

LPTX RSI Chart

LPTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

LPTX Valuation

Market Cap

49.3M

Price/Earnings (Trailing)

-0.97

Price/Sales (Trailing)

28.99

EV/EBITDA

-0.82

Price/Free Cashflow

-0.93

LPTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.85

Target 3M

$0.95

Target 6M

$0.9

LPTX Fundamentals

LPTX Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

-86.24%

Rev. Growth (Qtr)

-50%

LPTX Earnings

Earnings (TTM)

-50.8M

Earnings Growth (Yr)

81.83%

Earnings Growth (Qtr)

80.15%

LPTX Profitability

EBT Margin

-2858.12%

Return on Equity

-1.9K%

Return on Assets

-445.76%

Free Cashflow Yield

-107.12%

LPTX Investor Care

Shares Dilution (1Y)

47.85%

Diluted EPS (TTM)

-1.2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20253.0M2.4M1.7M0
20241.6M2.0M2.5M0
20232.3M2.0M1.9M1.1M
20221.4M1.6M1.8M2.1M
20211.8M1.8M2.9M1.2M
20202.2M2.5M2.8M1.8M
20191.0M1.3M1.6M1.9M
20181.5M1.2M995.8K756.0K
20172.8M2.4M2.1M1.7M
20160003.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About Leap Therapeutics Inc

LPTX
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEleaptx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES44

Leap Therapeutics Inc Frequently Asked Questions

LPTX is the stock ticker symbol of Leap Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Leap Therapeutics Inc is 49.29 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check LPTX's fair value in chart for subscribers.

The fair value guage provides a quick view whether LPTX is over valued or under valued. Whether Leap Therapeutics Inc is cheap or expensive depends on the assumptions which impact Leap Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LPTX.

As of Tue Jan 27 2026, LPTX's PE ratio (Price to Earnings) is -0.97 and Price to Sales (PS) ratio is 28.99. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LPTX PE ratio will change depending on the future growth rate expectations of investors.